Analyst Price Targets — ALLO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 11:44 am | — | Bernstein | $3.85 | $3.06 | TheFly | Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein |
| April 14, 2026 11:28 am | — | Robert W. Baird | $9.00 | $3.06 | TheFly | Allogene Therapeutics price target raised to $9 from $7 at Baird |
| May 16, 2024 6:44 am | Debjit Chattopadhyay | H.C. Wainwright | $9.00 | $2.98 | StreetInsider | Allogene (ALLO) PT Lowered to $9 at H.C. Wainwright |
| May 14, 2024 7:33 am | Kalpit Patel | B.Riley Financial | $7.00 | $2.90 | StreetInsider | Allogene (ALLO) PT Lowered to $7 at B.Riley |
| June 13, 2022 11:19 pm | Jack Allen | Robert W. Baird | $11.00 | $9.74 | Pulse 2.0 | Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird |
| January 3, 2022 12:00 am | Michael Schmidt | Guggenheim | $35.00 | $15.29 | TheFly | Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim |
| December 3, 2021 12:00 am | John Newman | Canaccord Genuity | $55.00 | $17.62 | TheFly | Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord |
| October 8, 2021 12:00 am | Anthony Butler | Roth Capital | $35.00 | $13.13 | TheFly | Allogene Therapeutics price target lowered to $35 from $60 at Roth Capital |
| October 8, 2021 12:00 am | Jason Gerberry | Bank of America Securities | $32.00 | $13.13 | StreetInsider | Allogene (ALLO) PT Lowered to $32 at BofA Securities |
| October 8, 2021 12:00 am | Mark Breidenbach | Oppenheimer | $40.00 | $13.13 | TheFly | Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer |
Latest News for ALLO
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) shares shot up 13.1% during mid-day trading on Thursday after JPMorgan Chase and Co. upgraded the stock from an underweight rating to a neutral rating. The company traded as high as $2.45 and last traded at $2.4550. 4,605,023 shares were traded during trading, a decline of 45%
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. In addition, the underwriters partially exercised their option and purchased 12,700,000 additional shares of common stock. Including the…
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of pre-clinical data for ALLO-329 in Nature Communications. ALLO-329 is an investigational allogeneic CAR T product developed…
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds from this offering are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALLO.
U.S. House Trading
No House trades found for ALLO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.